Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Initiated global VYVGART (efgartigimod alfa-fcab) commercial launch Expect data from five registrational trials of efgartigimod by first quarter of 2023 Announcing four new efgartigimod indications
Regulatory News: Celyad Oncology SA (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for
VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65)
Regulatory News: Celyad Oncology SA (Euronext Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric